Imunon Inc

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm engages in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IMUNON reports Q1 loss, highlights promising cancer treatment progress

IMUNON shows progress in clinical trials with promising data; strong leadership and innovative technology driving growth. Financial challenges exist, but opportunities in expanding therapeutic applications and COVID vaccine development are promising.

Imunon Inc reports Q2 losses, optimistic on clinical advancements

Imunon Inc faces financial challenges but shows promise in clinical outcomes.
Strategic expense management and positive study results are key strengths.
Opportunities lie in partnerships, financing, and upcoming data releases.
Leadership's optimism reflects confidence in the company's progress.

Imunon Inc reports positive clinical results and secures funding for growth

Imunon Inc's Q3 2024 performance reflects promising clinical advancements and financial stability, with plans for a Phase III trial in the pipeline.
The company's strengths lie in strong clinical data, secured funding, strategic partnerships, and a focus on innovation in cancer therapies.
Challenges include managing increased expenses, navigating partnerships, competition, and regulatory hurdles, requiring careful strategic planning.
Opportunities abound in advancing to Phase III trials, exploring partnerships for the COVID-19 vaccine, and leveraging strategic hires for growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Imunon, Inc. is a clinical stage oncology drug company. It focuses on cancer treatments, including directed chemotherapies, DNA-mediated immunotherapy and RNA-based therapies. The firm is also engaged in the research and development of pharmaceutical products for cancer treatments. Its portfolio includes deoxyribonucleic acid-mediated immunotherapy and ribonucleic acid-based therapies. It operates through the Celsion and ThermoDox brands. The company was founded by Yim-Pan Cheung in 1982 and is headquartered in Lawrenceville, NJ.

LAWRENCEVILLE, N.J., Dec. 01, 2022 (GLOBE NEWSWIRE) -- I MUNON , Inc.  (NASDAQ: IMNN), a clinical-stage drug development company, announces that Khursheed Anwer, Ph.D., the company's Executive Vice President and Chief Science Officer, presented today at the World Vaccine & Immunotherapy Congress in San Diego. Dr. Anwer highlighted the PLACCINE modality and proof-of-concept rodent and non-human primate data in SARS-CoV-2. PLACCINE is IMUNON's non-viral, non-device plasmid DNA-based vaccine modality targeting multiple antigens from a single vector.

IMUNON Presentation at World Vaccine & Immunotherapy Congress Highlights PLACCINE Preclinical Proof of Concept and Key Competitive Advantages

LAWRENCEVILLE, N.J., Nov. 22, 2022 (GLOBE NEWSWIRE) -- I MUNON , Inc.  (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer and Mr. Jeffrey Church, Executive Vice President and Chief Financial Officer will participate in A.G.P.'s Biotech Conference taking place virtually on November 30, 2022 through December 1, 2022.

IMUNON to Participate in the A.G.P./Alliance Global Partners Virtual Biotech Conference on November 30, 2022 – December 1, 2022

Investment of $375,000 with Senior Convertible Note s and Warrants; Strengthens Development Capabilities for IMUNON 's PLACCINE DNA Vaccine Platform

IMUNON Announces Strategic Investment in Transomic Technologies

Imunon, Inc. (NASDAQ:IMNN ) Q3 2022 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Kim Golodetz - Investor Relations Corinne Le Goff - President and Chief Executive Officer Jeffrey Church - Chief Financial Officer Khursheed Anwer - Chief Science Officer Nicholas Borys - Chief Medical Officer Conference Call Participants Emily Bodnar - H.C. Wainwright & Co, LLC James Molloy - Alliance Global Partners David Bautz - Zacks Small-Cap Research Operator Good morning.

Imunon, Inc. (IMNN) Q3 2022 Earnings Call Transcript

IMUNON Reports Third Quarter 2022 Financial Results and Provides Business Update

Successful combination of technologies will expand the opportunities for I MUNON 's DNA-based modality and broaden application s for the PLACCINE n ucleic a cid v accine p latform as a n alternative to mRNA and protein vaccines

IMUNON Enters into Technology Evaluation Agreement with Acuitas Therapeutics to Evaluate IMUNON's PLACCINE Plasmid DNA with Acuitas' Lipid Nanoparticle Delivery System

LAWRENCEVILLE, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Imunon, Inc. (NASDAQ: IMNN), a clinical-stage drug-development company focused on DNA-mediated immunotherapy and next-generation vaccines, announced today that the Company will host a conference call at 11:00 a.m. ET on Monday, November 14, 2022 to discuss financial results for the third quarter ended September 30, 2022 and provide an update on its clinical development of GEN-1, a DNA-based interleukin-12 (IL-12) immunotherapy in Phase II clinical development for the treatment of advanced-stage ovarian cancer, and its preclinical studies of PLACCINE, a proprietary, multivalent DNA-based plasmid technology utilizing synthetic, non-viral delivery vectors, being evaluated in proof-of-concept studies for superiority over current mRNA vaccines.

Imunon to Hold Third Quarter 2022 Financial Results and Business Update Conference Call on Monday, November 14, 2022

CEO of Curis brings extensive biopharmaceutical financial experience to the Board

Imunon Appoints James E. Dentzer to its Board of Directors

Supports PLACCINE Platform as a Viable Alternative to mRNA Vaccines

Imunon Reports Partial Results from Ongoing Non-human Primate Study

LAWRENCEVILLE, N.J., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Imunon , Inc.  (NASDAQ: IMNN), a clinical-stage drug development company, today announced that Dr. Corinne Le Goff, President and Chief Executive Officer will present a company overview and be available for 1x1 meetings at the upcoming Chardan 6th Annual Genetic Medicines Conference. The conference will be held on October 3-4 with in-person participation held at the Westin Grand Central Hotel in New York City.

IMUNON to Present at Chardan's 6th Annual Genetic Medicines Conference

News for Imunon Inc Stock (IMNN)